A Deep Dive into Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2025: Key Drivers, Growth Factors, and Projections 2025-2034

How Are the key drivers contributing to the expansion of the sodium glucose cotransporter 2 (sglt2) inhibitors market?
The rising prevalence of diabetes is likely to fuel the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market. Diabetes, a metabolic disorder that leads to high blood sugar, is becoming more common due to factors like urbanization, stress, environmental pollutants, and limited access to healthcare. SGLT2 inhibitors are used in diabetes management by preventing glucose reabsorption in the kidneys, helping lower blood sugar levels. They also offer cardiovascular and renal benefits. For instance, in December 2023, the Australian Bureau of Statistics reported that 5.3% of Australians (around 1.3 million people) were diagnosed with diabetes in 2022, with a higher prevalence among older age groups. Consequently, the rising diabetes rates are contributing to the growth of the SGLT2 inhibitor market.

Get Your Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Report Here:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

What growth opportunities are expected to drive the sodium glucose cotransporter 2 (sglt2) inhibitors market's CAGR through 2034?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market has experienced strong growth in recent years. It will grow from $10.17 billion in 2024 to $11.07 billion in 2025, at a CAGR of 8.8%. The growth can be attributed to successful early clinical trials, increasing regulatory approvals, rising diabetes diagnosis rates, and a growing demand for innovative treatments for diabetes.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market is anticipated to grow strongly, reaching $15.4 billion by 2029 with a CAGR of 8.6%. Growth will be fueled by rising diabetes and obesity rates, greater awareness of diabetes management, and expanding use in heart and kidney disease treatments. Key trends include combination therapies, personalized medicine, technological advancements, and traditional drug development.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

What are the emerging trends shaping the future of the sodium glucose cotransporter 2 (sglt2) inhibitors market?
Companies in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are developing dual inhibitor therapies to improve blood sugar management and patient outcomes. These therapies target both SGLT1 and SGLT2 to treat conditions like heart failure and diabetes. In May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, received FDA approval for sotagliflozin, a dual inhibitor for heart failure. This once-daily tablet helps reduce cardiovascular death and hospitalizations, particularly in adults with heart failure, type 2 diabetes, and chronic kidney disease, by reducing glucose and sodium reabsorption.

Which growth-oriented segments of the sodium glucose cotransporter 2 (sglt2) inhibitors market are leading the industry's development?
The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented -

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics

Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin), Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin), Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin), Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes, Suglat (Sotagliflozin) For Heart Failure

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

Which geographical regions are pioneering growth in the sodium glucose cotransporter 2 (sglt2) inhibitors market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the sodium glucose cotransporter 2 (sglt2) inhibitors market?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

What Is Covered In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report?

•Market Size Forecast: Examine the sodium glucose cotransporter 2 (sglt2) inhibitors market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the sodium glucose cotransporter 2 (sglt2) inhibitors market for a structured understanding.
•Key Players Overview: Analyze major players in the sodium glucose cotransporter 2 (sglt2) inhibitors market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the sodium glucose cotransporter 2 (sglt2) inhibitors market.
•Segment Contributions: Evaluate how different segments drive overall growth in the sodium glucose cotransporter 2 (sglt2) inhibitors market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the sodium glucose cotransporter 2 (sglt2) inhibitors market.
•Industry Challenges: Identify potential risks and obstacles affecting the sodium glucose cotransporter 2 (sglt2) inhibitors market.
•Competitive Landscape: Review strategic developments in the sodium glucose cotransporter 2 (sglt2) inhibitors market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.